BGI’s Non-Invasive Down Syndrome Test Approved by CFDA

BGI Diagnostics of Shenzhen announced that its non-invasive prenatal test, which is based on a sample of maternal blood, was approved by the CFDA. The NIFTY™ kit tests for chromosomal abnormalities at Trisomy 21 (Down Syndrome), 13 (Patau Syndrome) and 18 (Edwards Syndrome). According to BGI, the next-generation test is the only certified non-invasive prenatal test available in China. Earlier this year, the CFDA banned the use or manufacture of any unapproved prenatal test in China. More details.... Share this with colleagues: // //